Related references
Note: Only part of the references are listed.Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders
Malgorzata Mikulska et al.
BRITISH JOURNAL OF HAEMATOLOGY (2023)
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Livio Pagano et al.
BLOOD (2022)
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Yair Herishanu et al.
BLOOD (2022)
COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion
Clare Sun
BRITISH JOURNAL OF HAEMATOLOGY (2022)
COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity
Yandong Shen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
Cristina Bagacean et al.
BLOOD ADVANCES (2022)
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
J. Erika Haydu et al.
BLOOD ADVANCES (2022)
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Carsten U. Niemann et al.
BLOOD (2022)
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
Yotam Bronstein et al.
CANCER CELL (2022)
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
Helen Parry et al.
CANCER CELL (2022)
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Ohad Benjamini et al.
HAEMATOLOGICA (2022)
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Jose Luis Pinana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg et al.
LANCET (2022)
TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19
Joe B. Harford et al.
VIRUSES-BASEL (2022)
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Aekkachai Tuekprakhon et al.
CELL (2022)
WHAT THE LATEST OMICRON SUBVARIANTS MEAN FOR THE PANDEMIC
Ewen Callaway
NATURE (2022)
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
Nicole P. Hachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study
Isobel L. Ward et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Maria Stefania Infante et al.
FRONTIERS IN ONCOLOGY (2022)
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
Francesca Romana Mauro et al.
LEUKEMIA (2021)
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Thomas Chatzikonstantinou et al.
LEUKEMIA (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
Lindsey E. Roeker et al.
LEUKEMIA (2021)
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Lindsey E. Roeker et al.
BLOOD (2021)
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
H. Parry et al.
BLOOD CANCER JOURNAL (2021)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato et al.
BLOOD (2020)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfo et al.
LEUKEMIA (2020)
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Moritz Fuerstenau et al.
LEUKEMIA (2020)
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
Lindsey E. Roeker et al.
LEUKEMIA (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Ibrutinib may impair serological responses to influenza vaccination
Abby P. Douglas et al.
HAEMATOLOGICA (2017)
Ibrutinib may impair serological responses to influenza vaccination
Abby P. Douglas et al.
HAEMATOLOGICA (2017)
Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Clare Sun et al.
JAMA ONCOLOGY (2016)
Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
A Takaoka et al.
NATURE (2003)